Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products Parse Biosciences, a leading innovator in scalable and accessible single-cell sequencing technology, has reaffirmed its commitment to advancing its Evercode™ single-cell chromatin accessibility products. This announcement marks a significant milestone for…
Gensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies Gensaic, Inc., a pioneering biotechnology company leveraging AI-driven protein design and biological insights to develop precision ligands for targeted drug delivery, has announced a major discovery and license collaboration with…
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has unveiled promising preclinical data on SOT109, a next-generation antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17). These findings reinforce the strong therapeutic potential of SOT109 in treating colorectal cancer (CRC) and…
Revvity’s EUROIMMUN Secures CE Mark for Innovative Measles Antibody Test Revvity, Inc. (NYSE: RVTY) has announced the launch of EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG), which has received the CE mark. This novel assay is designed to support both the…
LabVantage Solutions Unveils LIMS 8.9: Transforming Lab Productivity and Efficiency LabVantage Solutions, Inc., a global leader in laboratory informatics, has announced the launch of LabVantage 8.9, the latest evolution of its cutting-edge Laboratory Information Management System (LIMS). This new release…
Protagonist and Takeda Announce Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ: PTGX) and Takeda (TSE: 4502/NYSE: TAK) have announced positive topline results from the Phase 3 VERIFY study, evaluating rusfertide in…
QIAGEN Takes Legal Action to Defend QuantiFERON Intellectual Property and Protect Innovations in Latent Tuberculosis Testing QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a patent infringement complaint against bioMérieux S.A. (EPA: BIM), reinforcing its commitment to protecting…
Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases Seismic Therapeutic, Inc., a pioneering machine learning immunology company, has announced the presentation of preclinical data for its novel immunoglobulin E (IgE) protease, S-8484. The data reveal S-8484’s ability to…
Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a leading biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases, has officially launched the Phase 3 ALPHA-ORBIT clinical trial of…
Immune-Onc Therapeutics Doses First Patient with IO-108 in Global Phase 1b/2 Liver Cancer Study in Collaboration with Roche Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage biopharmaceutical company focused on developing innovative therapies in immunology and oncology, has announced a significant…
Healx Begins Phase 2 Trial Dosing for HLX-1502 in Neurofibromatosis Type 1 Healx, an AI-driven, clinical-stage biotechnology company focused on developing treatments for rare diseases, has announced a major milestone in its efforts to provide new therapeutic options for patients…
Halda Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of HLD-0915 for Metastatic Castration-Resistant Prostate Cancer Halda Therapeutics, a clinical-stage biotechnology company focused on developing a novel class of cancer therapies known as RIPTAC™ (Regulated Induced Proximity Targeting Chimeras)…